Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.66
-0.21 (-3.58%)
At close: Apr 10, 2026, 4:00 PM EDT
5.55
-0.11 (-1.94%)
After-hours: Apr 10, 2026, 5:47 PM EDT
Savara Employees
Savara had 70 employees as of December 31, 2025. The number of employees increased by 11 or 18.64% compared to the previous year.
Employees
70
Change (1Y)
11
Growth (1Y)
18.64%
Revenue / Employee
n/a
Profits / Employee
-$1,697,671
Market Cap
1.43B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Biohaven | 274 |
| Precigen | 160 |
| Monte Rosa Therapeutics | 150 |
| Olema Pharmaceuticals | 131 |
| Nanobiotix | 103 |
SVRA News
- 5 days ago - Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 13 days ago - Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 4 weeks ago - Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 5 weeks ago - Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
- 7 weeks ago - Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 2 months ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire